OR WAIT 15 SECS
WCG has announced that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) is introducing a redesigned version of its Fox Trial Finder clinical study matching tool powered by WCG CenterWatch iConnect. Use of the iConnect platform will aim to make it easier for people with Parkinson’s disease (PD) and healthy volunteers to both find and participate in clinical trials.
“We are proud to be accelerating research and moving our mission forward to get safer, more effective treatments into the hands of patients living with Parkinson’s disease as efficiently as possible while maintaining the highest quality and ethical research standards. MJFF’s decision to redesign its new Fox Trial Finder on our iConnect platform will make clinical research much more accessible and easier to navigate for patients and their families,” said Donald A. Deieso, PhD, Executive Chairman and CEO of WCG.
“At the Foundation our single, urgent goal is to eliminate Parkinson’s disease. It will take the efforts of all of us to better connect the millions impacted by the disease worldwide to opportunities that could advance breakthroughs in treatments and ultimately a cure,” said MJFF Deputy CEO Sohini Chowdhury. “With 85 percent of trials facing delays and 30 percent never getting off the ground due to a lack of volunteers, the new Fox Trial Finder will reduce the burden of clinical trial recruitment by connecting patients and families to trials that urgently need them.”
WCG CenterWatch iConnect is visited by more than 250,000 unique users per month, who are searching for information about clinical trials for which they, a friend or family member may qualify.
WCG CenterWatch iConnect provides advanced trial listing technology for the largest patient advocacy groups in the world. It also allows sponsors to set up and manage all aspects of their patient recruitment programs from a single platform across the enterprise. This increased visibility enables them to determine the ROI and effectiveness of each tactic they employ across every study, improving predictability and reducing outreach expense.